SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant /x/
Filed by a party other than the Registrant / /
Check the appropriate box:
/ / Preliminary Proxy Statement
/ / Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
/ / Definitive Proxy Statement
/X/ Definitive Additional Materials
/ / Soliciting Material Pursuant to Section 240.14a-11(c) or Section
240.14a-12
Scios Inc.
- --------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
- --------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
/x/ No fee required
/ / Fee computed on table below per Exchange Act Rules 14a-6(i)(1)
and 0-11
(1) Title of each class of securities to which transaction applies:
- ------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
- ------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it was determined):
- ------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
- ------------------------------------------------------------------------
(5) Total fee paid:
- ------------------------------------------------------------------------
/ / Fee paid previously with preliminary materials.
/ / Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
------------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
------------------------------------------------------------------------
(3) Filing Party:
-----------------------------------------------------------------------
(4) Date Filed:
------------------------------------------------------------------------
<PAGE>
[SCIOS LETTERHEAD]
CONTACT:
Wendy Carhart
Scios Inc.
408/616-8325
FOR IMMEDIATE RELEASE:
SCIOS TO PRESENT p38 KINASE INHIBITOR PROGRAM
AS EXAMPLE OF NEXT GENERATION ANTI-INFLAMMATORY AGENT
SUNNYVALE, CA, January 25, 2000 - Scios Inc. (NASDAQ: SCIO) announced today that
Dr. George Schreiner, Vice President of Cardiorenal Research, will present
details of Scios' p38 kinase inhibitor program this week at the SMi
Pharmaceutical Conference "Advances in Anti Arthritic Agents." In his
presentation, Dr. Schreiner will describe the p38 kinase inhibitor program, as
an example of the next generation of anti-inflammatory drugs targeting
rheumatoid arthritis and other autoimmune diseases.
Scios plans to file an Investigational New Drug (IND) application with the U.S.
Food and Drug Administration during 2000, and begin Phase I clinical trials in
rheumatoid arthritis during the second half of 2000. Scios has developed highly
potent and orally active small molecule inhibitors of p38 kinase that block the
synthesis and action of Tumor Necrosis Factor (TNF). An inhibitor of TNF in pill
form should permit the effective treatment of rheumatoid arthritis with a
convenient and tolerable form of administration.
Dr. Schreiner noted that "Revolutionary changes in the treatment of rheumatoid
arthritis have taken place with the ability to lower TNF through injectable
proteins. Scios is developing small molecules that may have the same clinical
benefits in reducing the symptoms and progression of this disease, with the ease
of taking a pill once or twice a day. The Arthritis Foundation estimates that
2.1 million Americans suffer from rheumatoid arthritis."
-- more --
<PAGE>
January 25, 2000
Page 2 of 2
Scios Inc.
Scios is a biopharmaceutical company engaged in the discovery, development, and
commercialization of novel human therapeutics. Scios has commercial or research
and development relationships with Chiron Corporation, The DuPont
Pharmaceuticals Company, Eli Lilly and Company, GenVec Inc., Kaken
Pharmaceutical Co., Ltd., and Novo Nordisk A/S of Denmark. Scios' Psychiatric
Sales and Marketing Division successfully markets seven psychiatric products,
including co-promotion arrangements with Janssen Pharmaceutica's Risperdal(R)
(risperidone) and SmithKline Beecham's Paxil(R) (paroxetine hydrochloride).
Additional information on Scios is available at its web site located at
www.sciosinc.com and in the Company's various filings with the Securities and
Exchange Commission.
The statements in this press release that are not historical facts are
forward-looking statements that involve risks and uncertainties, and include the
risk of timely and successful completion of the p38 kinase inhibitor program,
the risks associated with development and commercialization of the Company's
products, as well as other risks detailed from time to time in the reports filed
by Scios with the SEC, including the Company's annual report on Form 10-K for
the year ended December 31, 1998 and subsequent reports on Form 10-Q.
-- end --
